 |
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hemodynamics and Vascular Regulation |
Department of Medicine, Division of Nephrology and Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
Address correspondence to: Dr. Daniel Batlle, Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Nephrology & Hypertension, 303 East Chicago Ave., SRL 10-475, Chicago, IL 60611-3008. Phone: 312-908-8342; Fax: 312-503-0622; E-mail: d-batlle{at}northwestern.edu
Received for publication May 1, 2006. Accepted for publication August 12, 2006.
Angiotensin-converting enzyme 2 (ACE2) expression has been shown to be altered in renal tubules from diabetic mice. This study examined the localization of ACE and ACE2 within the glomerulus of kidneys from control (db/m) and diabetic (db/db) mice and the effect of chronic pharmacologic ACE2 inhibition. ACE2 co-localized with glomerular epithelial cell (podocyte) markers, and its localization within the podocyte was confirmed by immunogold labeling. ACE, by contrast, was seen only in glomerular endothelial cells. By immunohistochemistry, in glomeruli from db/db mice, strong ACE staining was found more frequently than in control mice (db/db 64.6 ± 6.3 versus db/m 17.8 ± 3.4%; P < 0.005). By contrast, strong ACE2 staining in glomeruli from diabetic mice was less frequently seen than in controls (db/db 4.3 ± 2.4 versus db/m 30.6 ± 13.6%; P < 0.05). For investigation of the significance of reduced glomerular ACE2 expression, db/db mice were treated for 16 wk with a specific ACE2 inhibitor (MLN-4760) alone or combined with telmisartan, a specific angiotensin II type 1 receptor blocker. At the end of the study, glomerular staining for fibronectin, an extracellular matrix protein, was increased in both db/db and db/m mice that were treated with MLN-4760. Urinary albumin excretion (UAE) increased significantly in MLN-4760–treated as compared with vehicle-treated db/db mice (743 ± 200 versus 247 ± 53.9 µg albumin/mg creatinine, respectively; P < 0.05), and the concomitant administration of telmisartan completely prevented the increase in UAE associated with the ACE2 inhibitor (161 ± 56; P < 0.05). It is concluded that ACE2 is localized in the podocyte and that in db/db mice glomerular expression of ACE2 is reduced whereas glomerular ACE expression is increased. The finding that chronic ACE2 inhibition increases UAE suggests that ACE2, likely by modulating the levels of glomerular angiotensin II via its degradation, may be a target for therapeutic interventions that aim to reduce albuminuria and glomerular injury.
This article has been cited by other articles:
 |
|
 |
|
  E. Ritz How Little Aldosterone is Able to Raise Blood Pressure? Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 703 - 710. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Soler, M. Ye, J. Wysocki, J. William, J. Lloveras, and D. Batlle Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan Am J Physiol Renal Physiol, February 1, 2009; 296(2): F398 - F405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zimpelmann and K. D. Burns Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells Am J Physiol Renal Physiol, February 1, 2009; 296(2): F337 - F346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Soler, J. Wysocki, and D. Batlle Angiotensin-converting enzyme 2 and the kidney Exp Physiol, May 1, 2008; 93(5): 549 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ji, S. Menini, W. Zheng, C. Pesce, X. Wu, and K. Sandberg Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17{beta}-oestradiol regulation of renal pathology in renal wrap hypertension in rats Exp Physiol, May 1, 2008; 93(5): 648 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. S. Santos, A. J. Ferreira, and A. C. Simoes e Silva Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis Exp Physiol, May 1, 2008; 93(5): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tikellis, K. Bialkowski, J. Pete, K. Sheehy, Q. Su, C. Johnston, M. E. Cooper, and M. C. Thomas ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes Diabetes, April 1, 2008; 57(4): 1018 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Wong, G. Y. Oudit, H. Reich, Z. Kassiri, J. Zhou, Q. C. Liu, P. H. Backx, J. M. Penninger, A. M. Herzenberg, and J. W. Scholey Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury Am. J. Pathol., August 1, 2007; 171(2): 438 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Q. Velez, A. M. Bland, J. M. Arthur, J. R. Raymond, and M. G. Janech Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes Am J Physiol Renal Physiol, July 1, 2007; 293(1): F398 - F407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, L. Zagato, T. Kuznetsova, G. Tripodi, G. Zerbini, T. Richart, L. Thijs, P. Manunta, J.-G. Wang, G. Bianchi, et al. Angiotensin-Converting Enzyme I/D and {alpha}-Adducin Gly460Trp Polymorphisms: From Angiotensin-Converting Enzyme Activity to Cardiovascular Outcome Hypertension, June 1, 2007; 49(6): 1291 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ingelfinger ACE2: A New Target for Prevention of Diabetic Nephropathy? J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2957 - 2959. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
